Published in J Transl Med on January 05, 2012
Incorporation of membrane-anchored flagellin or Escherichia coli heat-labile enterotoxin B subunit enhances the immunogenicity of rabies virus-like particles in mice and dogs. Front Microbiol (2015) 0.86
Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine. J Biomed Nanotechnol (2015) 0.85
Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS One (2012) 0.82
Mucosal adjuvants for influenza virus-like particle vaccine. Viral Immunol (2013) 0.81
Effect of premedications in a murine model of asparaginase hypersensitivity. J Pharmacol Exp Ther (2015) 0.79
Bacillus subtilis spores as vaccine adjuvants: further insights into the mechanisms of action. PLoS One (2014) 0.78
Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model. BMC Infect Dis (2015) 0.78
Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant. J Virol (2015) 0.78
A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response. Sci Rep (2017) 0.78
A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen. PLoS One (2015) 0.77
A Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV. PLoS One (2015) 0.77
A Nanoparticle Based Sp17 Peptide Vaccine Exposes New Immuno-Dominant and Species Cross-reactive B Cell Epitopes. Vaccines (Basel) (2015) 0.77
Chimeric rabies virus-like particles containing membrane-anchored GM-CSF enhances the immune response against rabies virus. Viruses (2015) 0.76
The effects of HIV Tat DNA on regulating the immune response of HIV DNA vaccine in mice. Virol J (2013) 0.76
Characterization of novel Omp31 antigenic epitopes of Brucella melitensis by monoclonal antibodies. BMC Microbiol (2017) 0.75
Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines. PLoS One (2014) 0.75
Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection. Viruses (2016) 0.75
Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum Vaccin Immunother (2017) 0.75
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol (2003) 5.36
CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A (1996) 5.26
Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity (2001) 5.04
Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med (2009) 4.27
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med (1997) 4.12
Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med (1980) 3.95
Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell (2006) 3.23
CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol (1998) 2.93
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A (2010) 2.77
Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol (1996) 2.74
TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev (2008) 2.72
Macrophages ingest and are activated by bacterial DNA. J Immunol (1996) 2.64
Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med (1998) 2.58
Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol (2006) 2.38
IgG subclasses in bacterial infections. Monogr Allergy (1986) 2.32
Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect (2001) 2.26
Adjuvants for human vaccines--current status, problems and future prospects. Vaccine (1995) 2.26
Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol (2006) 2.20
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One (2008) 2.16
Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis (2005) 2.03
Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol (1996) 2.02
Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog (2009) 1.92
Virus-like particles: passport to immune recognition. Methods (2006) 1.89
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol (2009) 1.78
Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev (2004) 1.77
Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol (2005) 1.75
Currently approved prophylactic HPV vaccines. Expert Rev Vaccines (2009) 1.73
Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry (1976) 1.71
Transforming growth factor beta 1 selectivity stimulates immunoglobulin G2b secretion by lipopolysaccharide-activated murine B cells. J Exp Med (1993) 1.56
Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J Exp Med (2010) 1.54
The influence of virus structure on antibody responses and virus serotype formation. Immunol Today (1996) 1.50
CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol (1998) 1.48
Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol (1996) 1.39
Restricted Ig H chain V gene usage in the human antibody response to Haemophilus influenzae type b capsular polysaccharide. J Immunol (1991) 1.37
Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. J Virol (2001) 1.29
Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol (2006) 1.28
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A (2003) 1.26
Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. J Infect Dis (1986) 1.22
Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J Immunol (1997) 1.22
IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr Infect Dis J (1990) 1.20
IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses (2010) 1.18
Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses (2008) 1.18
Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis (2001) 1.16
Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol (2005) 1.15
Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol (2003) 1.13
Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antiviral Res (2002) 1.12
Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad Med J (1987) 1.10
Ability of monophosphoryl lipid A to augment the antibody response of young mice. Infect Immun (1988) 1.09
Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology (2009) 1.08
Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol (2002) 1.07
Improving vaccine performance with adjuvants. Clin Infect Dis (2000) 1.06
CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol (2001) 1.06
High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res (2001) 1.05
In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Virology (2007) 1.02
Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta (1999) 1.01
Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infect Immun (2003) 1.01
Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1. Acta Crystallogr D Biol Crystallogr (2001) 1.01
DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine (2007) 0.99
Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. J Transl Med (2005) 0.98
Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis (2010) 0.96
HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses (2001) 0.95
IgG subclasses to subviral components. Monogr Allergy (1988) 0.94
Virus-like particles: designing an effective AIDS vaccine. Methods (2006) 0.94
Virus-like particles as particulate vaccines. Curr HIV Res (2010) 0.94
Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics (2008) 0.92
A novel glycoprotein 120 sequence from an HIV type 1 isolate of the A clade identified in North Uganda. AIDS Res Hum Retroviruses (1998) 0.91
Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines (2009) 0.91
Effect of age on serum immunoglobulin G subclass antibody responses to inactivated influenza virus vaccine. J Med Virol (1994) 0.91
Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles. J Virol (2008) 0.90
Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice. Virol J (2009) 0.89
Human leukocyte IgG Fc receptors. Immunol Today (1986) 0.88
Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. Vaccine (2011) 0.87
Preliminary HPV vaccine results for women older than 25 years. Lancet (2009) 0.86
Immunoglobulin isotype-specific antibody responses to pneumococcal polysaccharide vaccine in patients with recurrent bacterial respiratory tract infections. Pediatr Res (1995) 0.86
Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant. J Biomed Biotechnol (2010) 0.82
MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. AIDS Res Hum Retroviruses (1999) 0.82
HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. Vaccine (2011) 0.78
Short communication: limited induction of IL-10 in PBMCs from HIV-infected subjects treated with HIV-VLPs. AIDS Res Hum Retroviruses (2009) 0.78
Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer (2009) 3.33
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics (2013) 1.24
Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agent Cancer (2012) 1.17
Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J Med Virol (2004) 1.13
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis. PLoS One (2013) 1.06
Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies. Oncology (2015) 1.03
Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population. J Med Virol (2006) 1.02
Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005. J Exp Clin Cancer Res (2009) 1.02
Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev (2010) 1.00
Human papillomavirus genotypes and HPV16 variants in penile carcinoma. Int J Cancer (2008) 0.99
Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. J Transl Med (2005) 0.98
Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review. Gynecol Oncol (2012) 0.97
Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis (2010) 0.96
Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women. J Gen Virol (2008) 0.96
Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol (2013) 0.95
Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med (2009) 0.95
Virus-like particles as particulate vaccines. Curr HIV Res (2010) 0.94
Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. Infect Agent Cancer (2007) 0.92
Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics (2008) 0.92
Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco. Transgenic Res (2008) 0.92
Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev Vaccines (2011) 0.91
Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines (2009) 0.91
Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89
Screening of HIV-1 isolates by reverse heteroduplex mobility assay and identification of non-B subtypes in Italy. J Acquir Immune Defic Syndr (2004) 0.89
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer (2008) 0.89
Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi's sarcoma lesions during pre-AIDS and AIDS era. Virology (2010) 0.89
Detection of mucosal and cutaneous human papillomaviruses in oesophagitis, squamous cell carcinoma and adenocarcinoma of the oesophagus. J Clin Virol (2009) 0.88
TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer (2011) 0.87
Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. Clin Dermatol (2013) 0.87
Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons? Immunotherapy (2011) 0.87
Cardiac tamponade and heart failure due to myopericarditis as a presentation of infection with the pandemic H1N1 2009 influenza A virus. J Clin Microbiol (2010) 0.87
Systems biology applied to vaccine and immunotherapy development. BMC Syst Biol (2011) 0.85
High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. Planta (2009) 0.84
Human papillomavirus infection in urine samples from male renal transplant patients. J Med Virol (2010) 0.83
New adjuvants in evolving vaccine strategies. Expert Opin Biol Ther (2011) 0.83
VLPs and particle strategies for cancer vaccines. Expert Rev Vaccines (2013) 0.83
Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS Lett (2009) 0.83
MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients. Biomarkers (2010) 0.82
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. J Transl Med (2014) 0.82
Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. J Transl Med (2010) 0.82
Somatic mutations of STK11 gene in human papillomavirus positive and negative penile cancer. Infect Agent Cancer (2013) 0.82
TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and Caucasian patients. Oncology (2009) 0.82
Infectious agents and human malignancies. Front Biosci (Landmark Ed) (2009) 0.82
Functional interaction between human papillomavirus type 16 E6 and E7 oncoproteins and cigarette smoke components in lung epithelial cells. PLoS One (2012) 0.82
A pilot study on the distribution of human papillomavirus genotypes and HPV-16 variants in cervical neoplastic lesions from Ecuadorian women. J Med Virol (2008) 0.82
Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example. Retrovirology (2007) 0.82
TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda. Cancer Detect Prev (2005) 0.81
Molecular epidemiology of human herpesvirus 8 variants in Kaposi's sarcoma from Iranian patients. Virus Res (2011) 0.81
Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy. Infect Agent Cancer (2008) 0.81
Characterization of the human papillomavirus (HPV) integration sites into genital cancers. Pathol Oncol Res (2012) 0.81